This episode introduces the critical distinction between solvable problems and permanent paradoxes within the healthcare and biotechnology industries. By examining corporate failures like Merck’s Vioxx crisis and Biogen’s Aduhelm launch, the author argues that leaders often default to an analytical mindset that mistakenly treats ethical tensions as binary equations. True leadership in these fields requires paradox fluency, which involves navigating the constant strain between commercial imperatives and patient safety rather than choosing one over the other. The source posits that these tensions are the operational home of ethics, meaning a collapse into simple problem-solving often results in mor ...